Description: Celonib is a pharmaceutical product available in the form of capsules, each containing 100 mg of Imatinib as the active ingredient. Imatinib is a tyrosine kinase inhibitor that plays a key role in the treatment of certain cancers and related conditions.

Composition: Each Celonib capsule comprises 100 mg of Imatinib mesylate, along with various excipients to ensure stability and proper formulation.

Uses: Celonib is prescribed for the treatment of various malignancies, notably chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). Imatinib works by inhibiting specific proteins that contribute to the growth and proliferation of cancer cells.

Usage and Dosage: The recommended dosage of Celonib is determined by the prescribing healthcare professional based on the patient’s specific medical condition, overall health, and other relevant factors. Patients should strictly adhere to the prescribed dosage and schedule.

Storage Conditions: Celonib capsules should be stored in a cool, dry place, away from direct sunlight, and at a controlled room temperature. It is essential to keep the medication out of the reach of children. Follow the storage instructions provided by the manufacturer to maintain the stability and efficacy of the product.

Mechanism of Action: Imatinib, the active ingredient in Celonib, is a selective tyrosine kinase inhibitor. It targets and inhibits the activity of specific tyrosine kinases involved in the abnormal growth and survival of cancer cells. By interfering with these signaling pathways, Imatinib helps to inhibit the proliferation of cancer cells and promotes apoptosis.

Contraindications: Celonib is contraindicated in individuals with known hypersensitivity to Imatinib or any other components of the formulation. It is essential to inform healthcare providers about any existing allergies or adverse reactions to medications.

Interactions: Imatinib may interact with other medications, and it is crucial for healthcare professionals to be aware of any concurrent drug therapies. Specific drugs, such as those metabolized by the CYP3A4 enzyme, may interact with Imatinib, potentially affecting its efficacy or increasing the risk of adverse effects.

Adverse Reactions: Common adverse reactions associated with Celonib may include nausea, diarrhea, muscle cramps, fatigue, and edema. Patients should promptly report any unusual or severe side effects to their healthcare provider. Regular monitoring and communication with the healthcare team are important to manage and address potential adverse reactions.

Patients should consult with their healthcare provider for personalized information regarding the use of Celonib, as individual responses to medication can vary.